["{\n\"step_by_step_thinking\": \"The relevant documents provide information on the treatment of gliomas, including malignant glioma. The most common and malignant glioma is glioblastoma multiforme. According to the document 'Treatment of gliomas in adults', the median survival of patients with glioblastoma is less than 20 months following treatment. There is no mention of dacomitinib as a treatment option for glioblastoma patients. Therefore, based on the provided information, it can be concluded that dacomitinib should not be used for treatment of glioblastoma patients.\",\n\"answer_choice\": \"B\"\n}"]